Breaking News Bar
updated: 12/18/2012 12:10 PM

Amgen to pay $762M settlement over drug marketing

hello
Success - Article sent! close
 
Associated Press

Amgen will pay $762 million to settle litigation that accuses the drugmaker of marketing the anemia drug Aranesp for unapproved uses.

A law firm involved in the case says the Thousand Oaks, Calif., company will pay a $612 million civil settlement, $136 million in criminal fines and a $14 million forfeiture.

Order Reprint Print Article
 
Interested in reusing this article?
Custom reprints are a powerful and strategic way to share your article with customers, employees and prospects.
The YGS Group provides digital and printed reprint services for Daily Herald. Complete the form to the right and a reprint consultant will contact you to discuss how you can reuse this article.
Need more information about reprints? Visit our Reprints Section for more details.

Contact information ( * required )

Success - request sent close

Amgen Inc. says it entered a conditional guilty plea to a misdemeanor count of misbranding Aranesp. The company took a $780 million charge last year for a possible settlement.

Amgen develops biologic medicines, or drugs produced by living cells rather than by mixing chemicals. Its settlement marks the latest between the U.S. Department of Justice and a drugmaker over improper marketing allegations.

Doctors can prescribe drugs for unapproved uses, but companies aren't allowed to market drugs for those uses.

Share this page
Comments ()
Guidelines: Keep it civil and on topic; no profanity, vulgarity, slurs or personal attacks. People who harass others or joke about tragedies will be blocked. If a comment violates these standards or our terms of service, click the X in the upper right corner of the comment box. To find our more, read our FAQ.
    help here